Latest News for: amyloidosis

Edit

After NC pastor’s heart failed, he walked — in extraordinary ways — to a new one

The Charlotte Observer 28 Aug 2025
Kelvis Reid, 66, reflects on a dramatic health journey that started with chest discomfort and ended with a first-of-its-kind dual organ transplant ... .
Edit

AL Amyloidosis Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | ...

GetNews 21 Aug 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market ... Some of the key takeaways from the AL Amyloidosis Pipeline Report..
Edit

Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy (Form 8-K) (Prothena Corporation plc)

Public Technologies 06 Aug 2025
Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy • ... treatment of ATTR amyloidosis with cardiomyopathy1-3.
Edit

What Is Cardiac Amyloidosis?

New York Times 04 Aug 2025
A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors ... .
Edit

Cardiac Amyloidosis Market Research 2025-2035 | Strategic Collaborations Accelerate Advances in Cardiac Amyloidosis Therapies - ResearchAndMarkets.com

Business Wire 26 Jul 2025
DUBLIN--(BUSINESS WIRE)--The "Cardiac Amyloidosis Market - A Global and Regional Analysis.
Edit

Cardiac Amyloidosis Market Research Report 2025-2035 Advancements In Targeted Therapies And Improved Access Fuel Steady Growth

MENA FN 18 Jul 2025
(MENAFN - GlobeNewsWire - Nasdaq) The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac conditions ... .
Edit

Cardiac Amyloidosis Market Research Report 2025-2035 | Advancements in Targeted Therapies and Improved Access Fuel ...

Nasdaq Globe Newswire 18 Jul 2025
The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac conditions ... The global cardiac amyloidosis market is ...
Edit

Update on CARES Phase III clinical program of anselamimab in light chain amyloidosis (AstraZeneca Pharmaceuticals LP)

Public Technologies 17 Jul 2025
AL amyloidosis is a rare, systemic and progressive disorder caused by defective plasma cells in the bone marrow ... Light Chain amyloidosis ... Worldwide, there are an estimated 74,000 patients living with AL amyloidosis.4,5 ... AL Amyloidosis.
Edit

Update on anselamimab in AL amyloidosis (AstraZeneca plc)

Public Technologies 16 Jul 2025
2025-07-16 08.00.00 CEST AstraZeneca PLC - Other information disclosed according to the rules of the Exchange Update on anselamimab in AL amyloidosis ... Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis.
Edit

Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis (Form 6-K) (AstraZeneca plc)

Public Technologies 16 Jul 2025
Update on anselamimab in AL amyloidosis ... Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis ... AL amyloidosis is a rare, systemic and progressive disorder caused by defective plasma cells in the bone marrow.
Edit

Landmark Study Shows Ultromics' EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography

PR Newswire 09 Jul 2025
Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure ... Study results demonstrate accuracy of EchoGo® Amyloidosis in detecting cardiac amyloidosis, with strong performance across AL, ATTRwt, and ATTRv subtypes.
Edit

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Nasdaq Globe Newswire 07 Jul 2025
– National Footprint of NEXICART-2 Trial Sites Expanded – ... .
Edit

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis

THe Post & Mail 13 Jun 2025
... (AL) amyloidosis in both the EU and USThe efficacy .
Edit

Alnylam Receives European Commission Approval for AMVUTTRA� (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Business Wire 09 Jun 2025
ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European ...
Edit

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did ...

Business Wire 24 May 2025
DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint ... .

Article Search

tools
×
×
×
×